Related Industries
|
Covington is widely recognized as a leader in the highly specialized field of royalty monetizations structured as sales directly to investors and through special purpose vehicles. We are well-versed in the use of monetizations to manage risk and raise capital to fund R&D and in-licensing activities, to develop product pipelines and help commercialize new products and to offset the costs of acquisitions. We advise all of the principal participants in these transactions, including financial and strategic investors, major universities, individual inventors and life sciences companies. Through our representation of all of the principal participants, we have developed a deep understanding of the perspectives of the participants in this novel and growing market that enables us to develop structures that satisfy the expectations of all parties.
Representative Matters
- A Fortune 100 Health Care Company in its creation and proposed sale of a synthetic royalty stream derived from licensing and supply arrangements for a pharmaceutical compound.
- A Fortune 100 Life Sciences Company in its sale of a pharmaceutical royalty stream from a biopharmaceutical company.
- A Fortune 100 Life Sciences Company in its sale of a pharmaceutical royalty stream from a global manufacturer of health care products.
- A Fortune 100 Pharmaceutical Company in its proposed acquisition of a minority interest in a pharmaceutical royalty stream from a biopharmaceutical company.
- A Fortune 100 Pharmaceutical Company in its proposed sale of four separate royalty streams.
- A Fortune 100 Pharmaceutical Company in the sale of a pharmaceutical royalty stream from a global biopharmaceutical company.
- An Inventor in the securitization of interests in royalties received by a major university as a result of the successful licensing of the Inventor’s compound.
- An Investment Fund in its proposed acquisition of a pharmaceutical royalty stream from a nationally recognized hospital.
- A Life Sciences Company in its proposed acquisition of a pharmaceutical royalty stream from a biopharmaceutical company.
- A Major Investment Fund in its proposed acquisition of a portfolio of royalty streams.
- A Major Investment Fund in its proposed acquisition of two royalty streams in the secondary market.
- A Major University in its proposed sale of a royalty interest associated with certain vaccines and diagnostic products.
- A Major University in its proposed sale of a royalty interest associated with internationally marketed vaccines.
- A Major University in its sale of a worldwide royalty interest in certain biopharmaceutical products.
- Emory University in the sale of its royalty interest in Emtriva for $540 million, IDD’s Healthcare Deal of the Year in 2005.
- Inventors in the sale of interests in royalties received by a major university as a result of the successful licensing (and sublicensing) of the Inventors’ compound.
- Northwestern University in the sale of a portion of its worldwide royalty interest in Lyrica for $700 million.
- Zurich Financial Services Group (Centre Solutions) in structuring and developing the first pharmaceutical royalty securitization ($130 million senior/subordinated financing) on behalf of a major university.
- Zurich Financial Services Group (Centre Solutions) in the sale of its interests in a pharmaceutical royalty stream to a leading royalty financier.
- Zurich Financial Services Group (Centre Solutions) with respect to two financings of, and purchases of equity rights associated with, two portfolios of specific pharmaceutical royalty streams.
|
|
|
|
|
|
|